RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $50
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $56 to $50.
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $56 to $50.